Central Bank & Trust Co. Sells 1,274 Shares of Thermo Fisher Scientific Inc. $TMO

Central Bank & Trust Co. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 70.3% in the third quarter, Holdings Channel reports. The fund owned 539 shares of the medical research company’s stock after selling 1,274 shares during the period. Central Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $364,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of TMO. Tsfg LLC grew its position in shares of Thermo Fisher Scientific by 20.4% in the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 19 shares during the period. Renasant Bank raised its holdings in Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after buying an additional 20 shares during the period. TCI Wealth Advisors Inc. lifted its stake in Thermo Fisher Scientific by 5.4% in the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock valued at $212,000 after buying an additional 22 shares in the last quarter. Legacy Wealth Managment LLC ID increased its position in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Finally, Chesapeake Wealth Management raised its holdings in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company’s stock worth $1,868,000 after acquiring an additional 22 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.3%

Shares of NYSE TMO traded up $8.17 during mid-day trading on Friday, hitting $660.15. The company had a trading volume of 493,268 shares, compared to its average volume of 2,244,326. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $694.33. The company has a market capitalization of $244.09 billion, a PE ratio of 35.49, a price-to-earnings-growth ratio of 2.77 and a beta of 0.87. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a 50-day simple moving average of $625.73 and a two-hundred day simple moving average of $540.54.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on TMO shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a report on Wednesday, August 5th. Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Finally, BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $634.86.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.